Q2 FY2026 EarningsQ2 FY2026 beat consensus on the top line with revenue of $162.3M vs. $159.1M expected, driven by 30.4% YoY growth in Clinical subscription revenue. Despite the revenue beat, gross margin of 70.3% slightly missed the 71.1% consensus due to a mix shift toward lower-margin Clinical services. Net income (GAAP) of $14.1M significantly exceeded the $6.6M consensus, aided by a $4.6M gain on debt extinguishment and a favorable tax benefit of $11.2M.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: WW(WW) the Revenue is 162.32 M (-14.19%), Beat estimate;the EBIT is 9.474 M (-83.17%), Miss estimate;the EPS is 1.41 (-90.47%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.16B14.19%
0.16B15.88%
+0.00B1.69%
EBITMiss expectations
0.01B83.17%
0.02B63.03%
-0.01B20.14%
EPSExceed expectations
1.4190.47%
0.66595.51%
+0.74505.04%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf